Qilu Pharmaceutical pays $38M upfront for greater China rights to Minghui's ADC
Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China biopharma Minghui Pharmaceutical.
Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China biopharma Minghui Pharmaceutical.
